- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has entered into a definitive agreement for a $20 million registered offering to institutional investors of Senior Convertible Notes and warrants. The transaction is expected to fund today. Seven Hills Partners LLC served as the placement agent for the transaction.
"We are pleased to announce this financing from a group of solid institutional investors familiar with both our market place and our long term prospects," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "This financing provides the company with a vehicle for long term continued investment in the company and allows us to focus on our core objectives of managing the business and improving our EBITDA performance."
The unsecured Senior Convertible Notes to be issued in the financing will bear interest annually at a rate of 6.25% per annum and will provide investors with the right to convert principal into registered shares of Nanogen common stock at $1.27 per share, which carries a premium of approximately 12% over the closing bid price of Nanogen's stock on August 24, 2007. The Notes have a three year term and, subject to certain conditions, the company may elect to make payments of interest in cash or stock. After 24 months, Nanogen will have the right to force conversion of the Notes into shares of the company's common stock, depending on the performance of the common stock. The company will initially place $7.3 million of the funds in a restricted bank account that will become unrestricted subject to certain stock price performance criteria.
Additionally, the investors initially received warrants to purchase approximately 11.0 million shares of common stock at an exercise price of $1.14 per share for a term of five years, which may be replaced with additional warrants if these initial warrants are exercised. Under certain circumstances, the company can force the exercise of these warrants, depending upon the performance of its common stock, which will provide the company access to additional capital.
Nanogen expects to use the net proceeds from the offering for working capital and general corporate purposes. For additional details concerning this transaction and the warrants, please see Nanogen's 8-K filed on August 27, 2007.
This press release is not an offer to sell or the solicitation of an offer to buy nor shall there be any sale of such Notes or Warrants in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities are being offered under the company's shelf registration statements filed with the Securities and Exchange Commission and only by means of a prospectus supplement, base prospectus and final term sheet, copies of which may be obtained from Seven Hills Partners, LLC, 275 Battery Street, 16th Floor, San Francisco, California 94111, collect: (415) 869-6223.
About Nanogen, Inc.
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChipģ electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Robert Saltmarsh, Chief Financial Officer
Suzanne Clancy, Corporate Communications
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
The intermediates in a chemical reaction photographed 'red-handed' Researchers at the UPV/EHU-University of the Basque Country have for the first time succeeded in imaging all the steps in a complex organic reaction and have resolved the mechanisms that explain it May 4th, 2016
Nuclear pores captured on film: Using an ultra fast-scanning atomic force microscope, researchers from the University of Basel have filmed 'living' nuclear pore complexes at work for the first time May 3rd, 2016